美国GeoVax  
GeoVax Inc.成立于2001年，致力于研发人类疫苗，尤其着重于研发一种HIV、AIDS疫苗，目前正在申请核准上市。公司位于美国东海岸，佐治亚州的亚特兰大市，由艾摩利大学(Emory University)的两位教授Dr. Robinson及Don Hildebrand与其它几位NIH和美国CDC的学者共同建立。
GeoVax的艾滋病疫苗技术，已发展超过15年，且已完成灵长类动物实验，灵长类动物实验的结果显示，96%有效，且有二十三分之二十二的疫苗接种者，在被可引起AIDS的病毒感染后，仍可受到保护。
第Ⅰ期的人体试验于2004年圆满完成。且GeoVax的AIDS疫苗已从2006年4月开始在美国的多个城市，进行人体临床试验。GeoVax也在评估于印度及非洲等艾滋病主要分布地区，扩展其HIV/AIDS疫苗试验之试验。
2006年的9月28日，GeoVax Inc. 和美国伊利诺伊州的Dauphin Technology, Inc.完成合并，两家公司合并后更名为GeoVax Labs, Inc.。因为合并的结果，GeoVax, Inc.先前的股东，目前大约拥有GeoVax Labs百分之六十九的股权。GeoVax Labs希望能藉由卖出价值一千一百万美元的证券继续进行集资，也因为卖出证券，过去GeoVax, Inc.股东的股份所有权百分比，将被稀释到大约67%。艾摩利大学先前拥有Geovax百分之四十八的股份，在合并之后，仍是最大股东，拥有该公司百分之三十三的股份。
在2004年取得AIDS疫苗的技术之后，今年GeoVax与Dauphin公司合并使公司资产与股东基础更加健全。合并后的公司，将更致力于进行中的临床人体试验，评估其AIDS疫苗的成效，以加速AIDS疫苗的发展，最终，希望能将产品授权销售于世界各地，希望能使数以百万计的生命，免除HIV-1病毒之威胁。

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents.
Our goals include: developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting phase 1, 2 and 3 human trials for vaccine safety and effectiveness, and obtaining regulatory approval of these vaccines in the USA and specified international markets.
In 2005, a phase 1 human clinical trial tested GeoVax's DNA vaccine. This trial concluded successfully, demonstrating the safety of our DNA vaccine(details).
After receiving ”Safe to Proceed” status for a new Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA), a phase 1 trial combining low doses of the DNA vaccine with the MVA vaccine began in May 2006. An additional phase 1 trial began in September 2006 to test full doses of the vaccines. In total, this phase 1 testing included four trials. All tested various combinations and doses of our DNA and MVA AIDS vaccines in human volunteers for their ability to raise Anti-AIDS immune responses as well as for their safety.
Successful results from all phase 1 testing of GeoVax's vaccines supported the initiation of the first phase 2 testing of our product. GeoVax's phase 2 human trial began in January 2009 and involves 225 participants at sites in the United States and South America.
Long term, we expect that GeoVax will enter into agreements to out-license manufacturing technology to major vaccine production companies and distribution rights to key companies in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacture and sale will be considered by GeoVax.